Raymond James Trust N.A. Sells 3,513 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Raymond James Trust N.A. lowered its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 53.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,015 shares of the company’s stock after selling 3,513 shares during the quarter. Raymond James Trust N.A.’s holdings in Henry Schein were worth $220,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in HSIC. Clarkston Capital Partners LLC increased its position in Henry Schein by 5.4% in the third quarter. Clarkston Capital Partners LLC now owns 1,397,805 shares of the company’s stock worth $101,900,000 after buying an additional 71,560 shares during the last quarter. Nuance Investments LLC increased its holdings in Henry Schein by 22.3% in the 3rd quarter. Nuance Investments LLC now owns 2,278,081 shares of the company’s stock worth $166,072,000 after acquiring an additional 414,748 shares during the last quarter. Thompson Siegel & Walmsley LLC bought a new stake in Henry Schein in the 2nd quarter valued at about $46,683,000. SG Americas Securities LLC lifted its holdings in Henry Schein by 1,622.3% during the third quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock valued at $33,449,000 after purchasing an additional 432,187 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new position in Henry Schein during the third quarter worth about $515,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Performance

Shares of HSIC opened at $77.66 on Friday. Henry Schein, Inc. has a 12-month low of $63.67 and a 12-month high of $82.63. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The company has a market cap of $9.68 billion, a PE ratio of 31.96, a price-to-earnings-growth ratio of 2.20 and a beta of 0.87. The stock has a 50-day moving average price of $71.26 and a 200-day moving average price of $69.84.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05. The business had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.32 EPS. As a group, equities analysts forecast that Henry Schein, Inc. will post 4.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Barrington Research reissued an “outperform” rating and issued a $82.00 price target on shares of Henry Schein in a research report on Wednesday, November 6th. Evercore ISI increased their target price on Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 8th. Robert W. Baird cut their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. JPMorgan Chase & Co. decreased their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Finally, StockNews.com upgraded Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Six investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $79.38.

Insider Buying and Selling at Henry Schein

In other news, COO Michael S. Ettinger sold 12,240 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the transaction, the chief operating officer now directly owns 87,706 shares in the company, valued at approximately $6,577,950. This represents a 12.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Lorelei Mcglynn sold 21,035 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the sale, the senior vice president now owns 71,833 shares of the company’s stock, valued at $4,978,026.90. The trade was a 22.65 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.